Lovelace Radiation Research in the Spotlight at National Convention

Lovelace Biomedical’s scientific team will share two recent examples of their advanced preclinical work in defining animal models for radiation research at the upcoming Radiation Research Society’s annual meeting, Oct. 15-18 in Cancun, Mexico.

The Tools and Talent to Investigate the Flu: A Unique CRO Capability

It was nearly a century ago, in 1918, that an influenza pandemic swept the world, killing as many as 40 million people. The “Spanish Flu,” as it was known, ended up causing nearly 675,000 deaths in the U.S., as it was a strain that quickly converted to pneumonia at a time when antibiotic drugs weren’t available.

Lovelace Respiratory Experts Measure Risks of e-Cigarettes

The Lovelace team has been performing cigarette-smoke inhalation exposure studies for more than 25 years, ranging from characterization of smoke to comparison of whole-body and nose-only exposure systems. We also are experts in measuring the toxicological effects of cigarette smoke inhalation exposure, using a variety of innovative methods and models depending on the needs of the study.

FEATURED WEBINAR: Innovation in Aerosol Drug Formulations

Get an inside look into a 15-year collaboration between the scientists at Lovelace Biomedical and engineers at Capsugel, a company that develops and manufactures dosage forms for the biopharmaceutical and consumer health industries.

Breathe Easy: Meeting the Preclinical Challenges of Pulmonary Fibrosis

The race is on for better therapies to treat pulmonary fibrosis, a chronic lung disease characterized by irreversible scarring of lung tissue. Though the condition is classified as a rare disease, its impact on patients is profound: nearly as many Americans die each year from the most common form of the disease, idiopathic pulmonary fibrosis (IPF), as from breast cancer.

Lovelace Biomedical Featured in The Scientist: Why Pharma Should Consider Canine Models for Alzheimer’s

Dr. Barrett explains the drug industry’s challenge to meet clinical endpoints for Alzheimer’s therapies that have shown promise in mice: “Despite researchers’ valiant efforts to stall, slow, or even beat this devastating neurodegenerative condition, there are still no effective drugs available to the estimated 5.4 million Americans with the disease.”